Engasertib for Osler-Weber-Rendu Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.
Are You a Good Fit for This Trial?
This trial is for adults (18+) with moderate to severe hereditary hemorrhagic telangiectasia (HHT), who have frequent nosebleeds, visible blood vessel spots on the skin or mouth, possible organ involvement, and either anemia or recent iron/blood transfusions.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Engasertib
Trial Overview
The study compares a daily dose of engasertib versus a placebo over 28 weeks to see if engasertib can reduce how often participants get nosebleeds. Participants are randomly assigned to one of the two groups without knowing which they receive.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive engasertib as an oral capsule QD for 28 weeks.
Participants will receive matching placebo as an oral capsule QD for 28 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vaderis Therapeutics AG
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.